Daewoong Pharmaceutical's Fexuclue Achieves 90% Complete Healing Rate for Gastric Ulcers After Endoscopic Procedures
Healing time shortened by 7 days
Daewoong Pharmaceutical's gastroesophageal reflux disease treatment Fexuclue (active ingredient: fexuprazan hydrochloride) achieved a higher complete healing rate than an existing treatment for gastric ulcers that developed after endoscopic procedures. The estimated time for the ulcers to heal completely was also about one week shorter.
On Nov. 20, Daewoong Pharmaceutical said that in a clinical trial involving 107 patients who underwent endoscopic submucosal dissection (ESD), the complete healing rate of gastric ulcers at eight weeks was 90.2% among patients treated with 40 mg of Fexuclue. This was 15.2 percentage points higher than the 75.0% rate among patients treated with 40 mg of esomeprazole. The multicenter, double-blind, randomized controlled trial was conducted from June 2024 through October 2026, comparing the two drugs when administered once daily for eight weeks.
ESD is a procedure in which tumors on the gastric mucosa are removed endoscopically. An artificial gastric ulcer forms at the site of resection after the procedure. If it does not heal sufficiently, the risk of complications increases, making management with acid-suppressing treatment important.
The treatments also differed in how quickly the ulcers healed. At both the four- and eight-week marks, the rate of ulcer shrinkage was significantly higher in the Fexuclue group than in the esomeprazole group. The estimated time to complete healing was 40.31 days for the Fexuclue group, about seven days shorter than the 47.22 days for the esomeprazole group. Positive results for healing time were also observed among patients whose ulcers covered an area of at least 800 mm².
The study results were presented as posters at major academic conferences in Korea and abroad. The paper was accepted for publication in the international journal World Journal of Gastroenterology in September and is scheduled to appear in January 2027.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Heo Cheol-ung, a professor at Yongin Severance Hospital and the study's principal investigator, said, "Fexuclue 40 mg achieved complete healing of gastric ulcers after ESD at a higher rate and more quickly than esomeprazole, with a similar level of safety. Shortening the time to complete healing by about seven days confirms the rapid and potent acid-suppressing effect of potassium-competitive acid blockers (P-CABs)."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.